Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 6:41 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 385–408 of 2,409 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Invasive Procedure Clear all

Conditions: Non-alcoholic Steatohepatitis, Chronic Liver Disease, HCV, NASH - Nonalcoholic Steatohepatitis, HIV Infection, Thrombocytopenia, Hepatitis C Virus, HBV, Human Immunodeficiency Virus, Liver Diseases, Hepatitis B Virus
Interventions: Eltrombopag, Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 292 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 33
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 28 more

Conditions: Asthma
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 5 Years to 17 Years
Enrollment: 128 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2010
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Bladder Cancer
Interventions: Not listed
Lead sponsor: Early is Good Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 3
States / cities: Little Rock, Arkansas • Indianapolis, Indiana • St Louis, Missouri

Conditions: Acute Compartment Syndrome
Interventions: Measurement of the Intra-Compartmental Pressure with the MY01 device; Device
Lead sponsor: McGill University Health Centre/Research Institute of the McGill University Health Centre; Other
Eligibility: 18 Years to 65 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 2
States / cities: Minneapolis, Minnesota • Nashville, Tennessee

Conditions: PTSD - Post Traumatic Stress Disorder
Interventions: transcutaneous auricular vagus nerve stimulation, sham transcutaneous auricular vagus nerve stimulation; Device
Lead sponsor: Wayne State University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2031
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Autonomic Dysfunction, Autonomic Imbalance, Autonomic Nervous System Diseases, Vagus Nerve Autonomic Disorder
Interventions: Standing-Squatting-Standing Test, Deep Breathing Test, Cold Pressor Test, Cold Face Test, Valsalva Maneuver, Transcutaneous Auricular Vagus Nerve Stimulation (taVNS); Other · Device
Lead sponsor: Northwell Health; Other
Eligibility: 18 Years to 60 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2027
U.S. locations: 1
States / cities: Manhasset, New York

Conditions: Anatomic Stage 0 Breast Cancer AJCC v8, Bilateral Breast Carcinoma, Breast Ductal Carcinoma In Situ, Invasive Breast Carcinoma, Multicentric Breast Carcinoma, Prognostic Stage 0 Breast Cancer AJCC v8
Interventions: Intraoperative Imaging, Lumpectomy; Procedure · Device
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 113 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 4
States / cities: Chicago, Illinois • Lexington, Kentucky • St Louis, Missouri + 1 more

Conditions: Obstructive Sleep Apnea of Adult
Interventions: ANNE Sleep; Device
Lead sponsor: Northwestern University; Other
Eligibility: 22 Years and older
Enrollment: 287 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 4
States / cities: Chicago, Illinois • Lake Forest, Illinois • Urbana, Illinois + 1 more

Conditions: Mild Cognitive Impairment
Interventions: sham tDCS, active tDCS; Device
Lead sponsor: University of Michigan; Other
Eligibility: 60 Years and older
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Metastatic Invasive Breast Cancer, Resistant Breast Cancer, ER+, HER2-, Metastatic Breast Cancer
Interventions: Neratinib + endocrine therapy, Endocrine therapy may include one of the following therapies: letrozole, anastrozole, exemestane, tamoxifen or fulvestrant, CDK4/6 + Endocrine therapy; Drug
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years and older · Female only
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2035
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Invasive Pulmonary Aspergillosis
Interventions: SCY-078, Voriconazole, Oral Placebo Tablets; Drug · Other
Lead sponsor: Scynexis, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 3
States / cities: Boston, Massachusetts • Ann Arbor, Michigan • Winston-Salem, North Carolina

Conditions: Glaucoma, Open Angle, MIGS, Minimally Invasive Glaucoma Surgery, Canaloplasty, Intraocular Pressure (IOP), Cataract Surgery, Surgical Technique, Minimally Invasive Surgical Technique, Glaucoma
Interventions: Retrospective chart review; Other
Lead sponsor: University of Utah; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Reduction of Unwanted Fat
Interventions: Zeltiq Dermal Cooling Device; Device
Lead sponsor: Zeltiq Aesthetics; Industry
Eligibility: 18 Years and older
Enrollment: 175 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2009
U.S. locations: 11
States / cities: Sacramento, California • San Diego, California • Washington D.C., District of Columbia + 8 more

Conditions: Breast Cancer
Interventions: multiple beams utilizing either intensity-modulated or 3D-conformal techniques; Radiation
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2027
U.S. locations: 8
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 5 more

Conditions: Urinary Bladder Neoplasm
Interventions: Mitomycin C; Drug
Lead sponsor: The University of Texas Health Science Center at San Antonio; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Mycoses
Interventions: Voriconazole; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: Not listed
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2003
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Lumbar Disease
Interventions: Pedicle Screw; Device
Lead sponsor: H Francis Farhadi, MD, PhD; Other
Eligibility: 18 Years to 80 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2020
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Coronary Artery Disease
Interventions: Rosuvastatin; Drug
Lead sponsor: General University Hospital, Prague; Other
Eligibility: 18 Years to 80 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 2
States / cities: Maywood, Illinois • Iowa City, Iowa

Conditions: Bladder Cancer, Urothelial Carcinoma, Urothelial Carcinoma Bladder
Interventions: UGN-103; Drug
Lead sponsor: UroGen Pharma Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 99 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 17
States / cities: Loma Linda, California • San Diego, California • Washington D.C., District of Columbia + 12 more

Conditions: Invasive Breast Carcinoma, Stage II Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage IIIA Breast Cancer
Interventions: Biopsy of Breast; Procedure
Lead sponsor: NRG Oncology; Other
Eligibility: 18 Years and older
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 377
States / cities: Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 256 more

Conditions: Gallbladder Disease
Interventions: SILS™ port laparoscopic cholecystectomy, Four Port Laparoscopic Cholecystectomy; Procedure
Lead sponsor: Medtronic - MITG; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 202 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 8
States / cities: New Haven, Connecticut • Tampa, Florida • Chicago, Illinois + 5 more

Conditions: Bladder Cancer
Interventions: Ethacrynic Acid; Drug
Lead sponsor: Eugene Lee, MD; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Kansas City, Kansas

Conditions: Candidiasis, Candidemia
Interventions: Micafungin, Caspofungin; Drug
Lead sponsor: Astellas Pharma Inc; Industry
Eligibility: 18 Years and older
Enrollment: 611 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 62
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Los Angeles, California + 49 more

Conditions: Spinal Cord Injury, Spasticity, Shockwave Therapy
Interventions: Focused extracorporeal shockwave therapy; Device
Lead sponsor: Kessler Foundation; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: West Orange, New Jersey

Search by objective public record fields.

Eltrombopag To Reduce The Need For Platelet Transfusion In Subjects With Chronic Liver Disease And Thrombocytopenia Undergoing Elective Invasive Procedures

Exhaled Breath Condensate as a Measure of Airway Inflammation in Children With Asthma

Clinical Evaluation of BCDx for Monitoring of Recurrence in Non-Muscle Invasive Bladder Cancer

Real-Time Muscle Pressure Measurements in Patients at Risk for Acute Compartment Syndrome

Understanding Non-invasive Vagus Nerve Stimulation Effects in PTSD

Non-Invasive Bioelectronic Analytics

Volumetric Specimen Imager Device for the Intraoperative Imaging of Patients With Breast Carcinoma and Breast Ductal Carcinoma In Situ, The VIVID Study

Comparative Study of the ANNE™ One System to Diagnose Obstructive Sleep Apnea

Multimodal Investigation of Neural Plasticity

Neu Direction: Testing the Efficacy of Adding HER Inhibition to Standard of Care in Metastatic MLH1-low Endocrine-resistant ER+/HER2- Breast Cancer

Evaluate Safety and Efficacy of the Coadministration of Ibrexafungerp With Voriconazole in Patients With Invasive Pulmonary Aspergillosis

Three Year Outcomes of Combined Hydrus Microstent With iTrack Canaloplasty

Non-Invasive Cooling of Fat Cells

Partial Breast Irradiation (PBI) Using 40 Gy for Select Patients With Early Invasive or Noninvasive Breast Cancer

Phase I Mitomycin Combined With Bacillus Calmette-Guérin (BCG) for Bladder Cancer

Emergency Use of Voriconazole in Patients With Life-Threatening Invasive Fungal Infections

Radiographic and Clinical Outcomes Following Unilateral or Bilateral Posterior Fixation in MI-TLIF

The Prediction of Extent and Risk Profile of Coronary Atherosclerosis and Their Changes During Lipid-lowering Therapy Based on Non-invasive Techniques

A Phase 3 Study of UGN-103 for Treatment of Patients With Low-grade Intermediate-risk Non-muscle Invasive Bladder Cancer

Assessing the Accuracy of Tumor Biopsies After Chemotherapy to Determine if Patients Can Avoid Breast Surgery

SILS™ Port Laparoscopic Cholecystectomy Post Market Study

Ethacrynic Acid Elimination in Non-Muscle Invasive Bladder Cancer Patients Undergoing Transurethral Resection

Study of Micafungin in Patients With Invasive Candidiasis or Candidemia

Shockwave for Elbow and Wrist Spasticity in People With Spinal Cord Injury